Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

University of Pittsburgh200 enrolled

Overview

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor: * immunologic assays/flow cytometry * tumor progression/regression * genomic studies * proteomic studies * others germane to the advancement of CTCL treatment

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Cutaneous T-cell Lymphoma Sezary Syndrome Mycosis Fungoides Eczema Atopic Dermatitis

Interventions

Blood draw, skin biopsy or urine collectionOTHER

Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 or older * able and willing to provide informed consent * diagnosed with CTCL * diagnosed with either atopic dermatitis or eczema Exclusion Criteria: * Lack of CTCL, atopic dermatitis, or eczema diagnosis in medical record

Locations (1)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

RECRUITING

Outcomes

Primary Outcomes

Proteomics of Cutaneous T-cell lymphoma

Proteomic variables will be measured in blood and tissue of consented CTCL patients.

Time frame: Ongoing

Central Contacts

Charity L Ruhl, LPN

CONTACT

4126472013 ruhlcl@upmc.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.